ALBIREO PHARMA Forum: Community User: COLOGNE79

https://biz.yahoo.com/e/160324/biod8-k.html

On March 22, 2016, Nasdaq notified the Company that while the Company had not regained compliance with the Bid Price Rule, it was eligible for an additional 180-day grace period, or until September 19, 2016, to regain compliance with the Bid Price Rule. Nasdaq's determination was based on the Company having met the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the The Nasdaq Capital Market, with the exception of the Bid Price Rule, and on the Company's written notice to Nasdaq of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If the Company does not regain compliance with the Bid Price Rule by September 19, 2016, Nasdaq will provide written notification to the Company that it's common stock will be delisted. At that time, the Company may appeal the delisting determination to a NASDAQ Hearings Panel (the "Panel"). The Company would remain listed pending the Panel's decision. There can be no assurance that, if the Company does appeal the delisting determination that such appeal would be successful.

Da sie heute noch an der nasdaq und nicht an der otc gehandelt wurde fristverlängerung durch?

ok. wurd gut gepusht durch sd

Bis 0.58?

Krasse Sache

hast schon ne meinung bis wo es ansteigen kann?

noch nicht ;)

jemand investiert?